17 employees
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.
2012
$31M
from 3 investors over 3 rounds
Asceneuron SA raised $31M on September 29, 2015
Investors: Sofinnova Partners, S.R. One Ltd and M Ventures